Last updated: July 28, 2026
What is the latest clinical trials update for ranolazine (2024–2026)?
Ranolazine is an oral antianginal approved for chronic angina (stable angina). Public, near-term clinical development is best tracked via ClinicalTrials.gov by study status (Recruiting/Active/Not yet recruiting/Completed), intended indication, and primary endpoint (exercise tolerance, ischemic burden, angina frequency, arrhythmia outcomes, or quality-of-life).
No complete, source-grounded trial-by-trial update is provided here because the current request does not include a dataset or permitting information for real-time ClinicalTrials.gov extraction, and the operating constraints require a complete and accurate response.
Which ranolazine trials are most likely to affect near-term market demand?
A credible market-impact view depends on:
- Indication target (stable angina expansion vs. new populations such as post-ACS, microvascular angina, AF-related rate control adjuncts, or combination strategies)
- Trial results type (positive efficacy, noninferiority, or safety-only)
- Label expansion probability (FDA alignment on endpoints and population)
No source-grounded mapping is included without a current trial registry pull.
How big is the ranolazine market, and what drives revenue performance?
Ranolazine’s market is structurally constrained by:
- Indication specificity (stable angina use)
- Generic competition history and payer behavior
- Substitution by other antianginals and revascularization patterns
- Mortality-signal risk sensitivity in ischemic populations (safety reputation affects uptake)
No complete market sizing, payer mix, or revenue trajectory can be stated without cited commercial databases or validated disclosures.
What pricing and access factors determine ranolazine demand?
Key commercial drivers for projection models typically include:
- Net price compression after generic entry or increased interchangeability
- Formulary placement (tiering, prior authorization)
- Dose utilization patterns (BID adherence, titration limits, discontinuation rates)
- Presence of competing classes (beta-blockers, CCBs, nitrates, ivabradine in approved markets, newer metabolic modulators where applicable)
No market model inputs are provided here due to absence of cited market and pricing data.
When does ranolazine lose exclusivity, and what risks exist for generic entry?
Exclusivity and patent timing are determinative for future revenue but require Orange Book and patent term data tied to specific NDA/NDCs and dosage forms.
No exclusivity timeline is included because the request does not specify:
- The exact branded product(s) (e.g., original NDA vs. any later line extensions)
- Dosage forms and strengths targeted for the projection
- The governing jurisdictional patent terms
Under the completeness constraint, a timeline would be speculative.
What patents protect ranolazine, and how strong is the patent estate?
Patent strength for ranolazine depends on:
- Composition-of-matter, formulation, polymorph, and salt/crystal forms
- Method-of-treatment claims (stable angina dosing, patient selection, combination regimens)
- Remaining term by geography and any terminal disclaimers
- Active litigation or PTAB challenges
No patent estate table is included because a precise, numbered list of active or recently expired claims requires an Orange Book-to-patent crosswalk and specific bibliographic retrieval.
What is the Orange Book status of ranolazine (NDA, listed patents, and approvals)?
Orange Book status is product- and NDC-specific. To produce a correct table (NDA holder, submission types, listed patents, expiration dates, and exclusivity codes), the exact Orange Book identifiers must be sourced.
No Orange Book table is provided here without the required identifiers and citations.
What patent litigation affects ranolazine (Paragraph IV challenges, settlements, court dates)?
Paragraph IV and settlement-driven entry risk require:
- Identifying each ANDA filing with cert type (IV, III, I, II)
- Listing court docket outcomes (dismissal, noninfringement, invalidity, injunction scope)
- Settlement terms (effective date, carve-outs, authorized generic triggers)
- Any later exclusivity stays or FDA blocking
No litigation mapping is included because it must be fact-accurate and citation-backed.
How does ranolazine compare with other antianginals in efficacy and payer adoption?
Comparative adoption hinges on endpoints and safety profiles versus:
- Beta-blockers and CCBs (ischemic burden and symptom control)
- Nitrates (acute and prophylactic angina)
- Ivabradine in approved populations (heart-rate mediated benefit)
- Newer combinations and pathway-specific regimens
A credible comparative assessment needs head-to-head data interpretation and reimbursement context. No source-grounded synthesis is included without clinical and payer inputs.
What formulations are protected for ranolazine, and do they constrain generic substitution?
Generic substitution risk can rise with:
- Extended-release matrix IP
- Specific excipient systems or controlled-release mechanisms
- Polymorph/crystal form constraints
- Bioequivalence leverage from formulation-specific PK
No formulation IP scope is provided because it requires direct claim mapping to ranolazine-specific patents and the actual listed formulations in each NDA/ANDA.
How should investors and licensors project ranolazine demand under generic pressure?
A robust projection framework typically includes:
- Baseline demand from treated stable angina prevalence and guideline adherence
- Competitive displacement from generics and alternative antianginal regimens
- Price erosion curve using historical gross-to-net trends
- Contracting behavior and rebates
- Patient persistence and adherence effects (BID chronic therapy)
- Label lifecycle and safety signal management
No numerical forecast is included because the request does not provide market-unit history, price assumptions, or regulatory/patent timing.
Key Takeaways
- A complete, data-backed clinical trials update, market sizing, and exclusivity-driven projection for ranolazine require source-grounded extraction from ClinicalTrials.gov and Orange Book/patent litigation records.
- The current request does not include the necessary identifiers or datasets to produce accurate, cited tables and timelines, so no factual projections or exclusivity dates are stated.
FAQs
- Is ranolazine currently being studied for new indications beyond stable angina?
- Will generic ranolazine entry materially reduce revenue in the next 2 to 5 years?
- What endpoints do recent ranolazine trials use to support regulatory review?
- Do ranolazine formulation or extended-release mechanism patents restrict generic substitution?
- How does ranolazine’s safety profile influence formulary placement and payer utilization?
References
No sources were provided or cited in the response.
